-
Quantum Hi-Tech (ChemPartner) Plans to Raise Over RMB 930 Million in Private Placement
•
Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149), is poised to raise a significant amount of capital through a private share placement. The company plans to issue 149,389,197 shares at a price of RMB 6.23 per share, which is expected to yield over RMB 930 million (USD…
-
Insilico Medicine Receives $10 Million Milestone Payment for XL309 Clinical Progress
•
Chengdu-based, generative artificial intelligence (AI)-driven clinical stage biotech company, Insilico Medicine, has announced the receipt of a $10 million clinical milestone payment from Exelixis following the progress of its XL309 (ISM3091) project in the clinical stage. XL309 is a selective, oral USP1 small molecule inhibitor discovered by Insilico Medicine using…
-
EOSVISION Ltd Secures Series A Funding to Advance Ophthalmic Implant Development
•
Suzhou-based EOSVISION Ltd has reportedly raised close to RMB 100 million (USD 13.78 million) in a Series A financing round, led by Dalton Venture. The proceeds from this investment will be allocated to bolster the company’s research and development (R&D), clinical studies, global development, regulatory filing, and marketing efforts for…
-
Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments
•
Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and California, the US, has announced the successful closing of a USD 120 million Series C financing round. The funding was led by Bain Capital Life Sciences and included contributions from Janus Henderson and existing investors…
-
MDHC Life Technologies Secures Series C++ Funding to Boost Consumer Healthcare and Life Sciences
•
China-based Contract Development Manufacturing Organization (CDMO) MDHC Life Technologies (Kunshan) Co.,Ltd has reportedly raised hundreds of millions of renminbi in a Series C++ financing round, led by FUN WAY AMC. The proceeds from this funding will be directed towards the development and operation of the company’s consumer healthcare and life…
-
Shanghai Unveils Action Plan and Fund for Biopharma M&A Activities
•
The Shanghai Municipal People’s Government has released the “Action Plan for Supporting Mergers and Acquisitions (M&A) of Listed Companies in Shanghai (2025-2027)”, which includes an allocation of an RMB 10 billion (USD 1.38 billion) fund specifically for M&A activities in the biopharmaceutical industry. Strategic M&A Targets and Global CompetitivenessThe document…
-
Hantech Medical Device Co., Ltd Acquires BD’s Villamarzana Factory to Expand Manufacturing
•
China-based Hantech Medical Device Co., Ltd, a Contract Development Manufacturing Organization (CDMO) specializing in medical consumables, has announced the buyout of Becton, Dickinson and Company’s (BD) factory located in Villamarzana, Italy. This acquisition includes all assets such as land, factory buildings, and equipment. Concurrently, the US major has reached an…
-
WuXi AppTec’s Subsidiary Invests EUR 20 Million in Jeito II S.L.P. for Growth Expansion
•
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec Co., Ltd (SHA: 603259) has announced that its wholly owned subsidiary, WuXi PharmaTech Healthcare Fund I L.P., is set to invest EUR 20 million (USD 21.12 million) by subscribing to A shares of Jeito II S.L.P. Jeito II S.L.P. Fund Managed…
-
Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion
•
China-based Jiaxing Pharbers Genesis has reportedly raised RMB 100 million (USD 13.74 million) in a Series A2 financing round. The round was led by the Beijing Isotope and Radiation Innovative Industry Investment Fund, which was initiated by China National Nuclear Corporation (CNNC) and China Isotope and Radiation Corporation, with participation…
-
Novo Holdings’ Acquisition of Catalent Gets EU Nod, Paving Way for Novo Nordisk Expansion
•
The acquisition of contract development and manufacturing organization (CDMO) Catalent (NYSE: CTLT) by Novo Holdings A/S, the controlling shareholder of Denmark’s major pharmaceutical company Novo Nordisk (NYSE: NVO), has been cleared by the European Commission (EC). This endorsement smooths the path for Novo Nordisk’s subsequent acquisition of three manufacturing sites…
-
Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion
•
Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised close to RMB 200 million (USD 27.5 million) via a Series B financing round. The round was led by Fir Health Capital with a contribution of RMB 50 million (USD 6.9 million), and was also…
-
Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development
•
China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has successfully placed 142 million shares through a private placement to compatriot firm Yangtze River Pharmaceutical (Group) Co., Ltd. This transaction positions Yangtze River Pharmaceutical as the largest shareholder of Jiangsu Recbio, marking a significant strategic investment in the biotechnology sector. Proceeds…
-
Sanofi Announces EUR 1 Billion Investment for New Beijing Manufacturing Plant
•
French pharmaceutical company Sanofi (NASDAQ: SNY) has announced plans to invest EUR 1 billion (USD 1.05 billion) in the construction of a new manufacturing plant in the Beijing Economic-Technological Development Area. This marks the company’s largest investment in China to date. Expanding Local Manufacturing Capacities for InsulinThe new facility will…
-
CBC Group and Mubadala Acquire UCB’s Neurology and Allergy Business in China for $680 Million
•
Singapore-based healthcare private equity firm CBC Group and Mubadala Investment Company, a global investment company based in Abu Dhabi, have jointly announced the strategic acquisition of Belgium-based biopharma UCB’s (FRA: UNC) mature neurology and allergy business in China. The deal is valued at USD 680 million and includes UCB’s well-known…
-
Affinity (Shanghai) Secures Over RMB 400 Million in Series B2 Financing to Advance Oncology Drugs
•
Affinity (Shanghai), the parent company of Shanghai Affinity Biopharmaceutical Co., Ltd., has reportedly raised upwards of RMB 400 million (USD 55 million) in a Series B2 financing round. The funding was led by CMG-SDIC Fund, with contributions from China Growth Capital, Hong Cheng Investment, and others. The proceeds will be…
-
Nanjing Leads Biolabs Commences IPO Process with Focus on Innovative Therapies
•
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, has officially submitted its IPO application to the Hong Kong Stock Exchange on November 29. The company, known for its robust pipeline of 12 innovative candidate drugs, has six of which…
-
Daiichi Sankyo Invests RMB 1.1 Billion in New ADC Manufacturing Plant in Shanghai
•
Japanese pharmaceutical company Daiichi Sankyo (TYO: 4568) is significantly increasing its investment in China with a RMB 1.1 billion outlay to establish a new antibody drug conjugate (ADC) manufacturing plant in Zhangjiang, located in Shanghai’s Pudong New Area. This strategic move by the firm is aimed at addressing the escalating…
-
Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs
•
Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs), has reportedly raised $42 million via a Series A financing round. The funding round was led by Lanchi Ventures, with additional contributions from YuanBio Venture Capital, Legend Capital, and Xiamen…
-
Adcendo ApS Secures Oversubscribed USD135 Million Series B Financing to Advance ADC Pipeline
•
Danish antibody drug conjugate (ADC) specialist, Adcendo ApS, has announced the completion of an oversubscribed Series B financing round, raising USD135 million. The proceeds from this round will be utilized to accelerate the development of its first-in-class ADC pipeline, which includes the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05,…
-
Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced revisions to its private placement plan, downsizing the initially disclosed proceeds from RMB 2.608 billion (USD 360 million) in April to RMB 1.848 billion (USD 255.1 million). The adjusted funds will be allocated towards new drug research and development, a global-aligned…
